Log In
BCIQ
Print this Print this
 

galeterone (TOK-001)

  Manage Alerts
Collapse Summary General Information
Company Tokai Pharmaceuticals Inc.
DescriptionSelective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20 lyase (CYP17; CYP17A) inhibitor
Molecular Target Androgen receptor ; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A)
Mechanism of ActionCytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor; Androgen receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationPancreatic cancer
Indication DetailsTreat pancreatic cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$9.3M

$9.3M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/16/2015

$9.3M

$9.3M

0

Get a free BioCentury trial today